Oct. 18 at 10:21 PM
$NRSN People forget that biotech breakouts never happen when everyone expects them. Look at
$ATHA,
$ANVS,
$AMLX, all were completely dead for weeks before exploding 300 to 600 percent. Same setup here: AI based patient stratification, strong Phase 2 data in ALS and Alzheimer’s, and a ready to go Phase 3 program waiting for funding or a deal.
No hype, no noise, no attention, exactly how it looked before the big runs in 2022 to 2024. The difference now is that NRSN targets two major diseases and combines it with AI driven biomarker precision. The market doesn’t understand it yet, but when the announcement comes, it won’t wait.
Quiet periods like this are not weakness. They are compression before the spring snaps.
